Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study - 30/07/24

Doi : 10.1016/S1470-2045(24)00211-0

Mohamad E Allaf, ProfMD ^a, Se-Eun Kim, MB ^c, Viraj Master, ProfMD ^d, David F McDermott, ProfMD ^e, Lauren C Harshman, MD ^f, Suzanne M Cole, MD ^h, Charles G Drake, ProfMD ^j, Sabina Signoretti, ProfMD ^k, Mahmut Akgul, MD ^l, Nicholas Baniak, MD ^m, Elsa Li-Ning, MD ⁿ, Matthew B Palmer, MD ^o, Hamid Emamekhoo, MD ^q, Nabil Adra, MD ^r, Hristos Kaimakliotis, MD ^s, Yasser Ged, MBBS ^b, Phillip M Pierorazio, ProfMD ^t, E Jason Abel, ProfMD ^u, Mehmet A Bilen, MD ^v, Kenneth Ogan, ProfMD ^w, Helen H Moon, MD ^x, Krishna A Ramaswamy, MD ^y, Eric A Singer, ProfMD ^z, Tina M Mayer, MD ^aa, Jay Lohrey, MD ^h, Vitaly Margulis, ProfMD ⁱ, Jessie Gills, MD ^ab, Scott E Delacroix, MD ^ac, Mark J Waples, MD ^ad, Andrew C James, MD ^ae, Peng Wang, MD ^af, Toni Choueiri, ProfMD ^g, M Dror Michaelson, MD ^ag, Anil Kapoor, ProfMD ^ah,^{^{†
Prof Kapoor died in February, 2023}}, Daniel Y Heng, ProfMD ^ai, Brian Shuch, MD ^aj, Bradley C Leibovich, ProfMD ^ak, Primo N Lara, ProfMD ^al, Judith Manola, MS ^c, Deborah Maskens, MA ^am, Dena Battle, BS ^an, Robert Uzzo, MD ^ao, Gennady Bratslavsky, ProfMD ^ap, Naomi B Haas, ProfMD ^p,^aq,^{*
Contributed equally}⁎ , Michael A Carducci, ProfMD ^b,^{*
Contributed equally}

^a Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

^b Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

^c Department of Data Science, Dana-Farber Cancer Institute/ECOG-ACRIN Biostatistics Center, Boston, MA, USA

^d Department of Urology, Emory University, Altanta, GA, USA

^e Division of Medical Oncology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA, USA

^f Department of Internal Medicine, Dana-Farber/Harvard Cancer Center, Boston, MA, USA

^g Department of Medical Oncology, Dana-Farber/Harvard Cancer Center, Boston, MA, USA

^h Department of Internal Medicine, UT Southwestern/Simmons Cancer Center-Dallas, Dallas, TX, USA

ⁱ Department of Urology, UT Southwestern/Simmons Cancer Center-Dallas, Dallas, TX, USA

^j Milstein Hospital, New York, NY, USA

^k Department of Pathology, Brigham and Women’s Hospital, Boston, MA, USA

^l Department of Pathology, Albany Medical Center, Albany, NY, USA

^m Department of Pathology and Laboratory Medicine, University of Saskatchewan, Saskatoon, SK, Canada

ⁿ Department of Translational Molecular Pathology, MD Anderson Cancer Center, Houston, TX, USA

^o Department of Pathology and Laboratory Medcine, University of Pennsylvania/Abramson Cancer Center, Philadelphia, PA, USA

^p Department of Medicine, University of Pennsylvania/Abramson Cancer Center, Philadelphia, PA, USA

^q Department of Medicine, Wisconsin Institute for Medical Research, Madison, WI, USA

^r Department of Hematology/Oncology, Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA

^s Department of Urology, Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA

^t Division of Urology, Department of Surgery, Penn Presbyterian Medical Center, Penn Medicine, Philadelphia, PA, USA

^u Department of Urology, University of Wisconsin Carbone Cancer Center, Madison, WI, USA

^v Department of Hematology and Medical Oncology, Emory University/Winship Cancer Institute, Atlanta, GA, USA

^w Department of Urology, Emory University/Winship Cancer Institute, Atlanta, GA, USA

^x Department of Research and Evaluation, Kaiser Permanente, Riverside, CA, USA

^y Department of Urology, Kaiser Permanente Oakland Medical Center, Oakland, CA, USA

^z Department of Urology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA

^aa Deparment of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA

^ab Department of Urology, Louisiana State University Health Science Center, New Orleans, LA, USA

^ac Department of Urology, Louisiana Cancer Research Center, New Orleans, LA, USA

^ad Department of Urology, Aurora Urology, Milwaukee, WI, USA

^ae Department of Urology, University of Kentucky/Markey Cancer Center, Lexington, KY, USA

^af Division of Medical Oncology, Ohio State University Comprehensive Cancer Center, Columbus, OH, USA

^ag Department of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA

^ah Department of Surgery, McMaster University, Hamilton, ON, Canada

^ai Department of Oncology, Tom Baker Cancer Centre, Calgary, AB, Canada

^aj Department of Urology, UCLA/Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA

^ak Department of Urology, Mayo Clinic, Rochester, MN, USA

^al Division Hematology and Oncology, University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA

^am International Kidney Cancer Coalition, Amsterdam NL, Guelph, ON, Canada

^an Kidney Cancer Research Alliance, Alexandria, VA, USA

^ao Department of Urology, Fox Chase Cancer Center, Philadelphia, PA, USA

^ap Department of Urology, SUNY Upstate Medical Center-Community Campus, Syracuse, NY, USA

^aq Perelman Center for Advanced Medicine, Philadelphia, PA, USA

^* Correspondence to: Prof Naomi B Haas, Perelman Center for Advanced Medicine, Philadelphia, PA 19104, USA Perelman Center for Advanced Medicine Philadelphia PA 19104 USA

Summary

Background

The standard of care for patients with intermediate-to-high risk renal cell carcinoma is partial or radical nephrectomy followed by surveillance. We aimed to investigate use of nivolumab before nephrectomy followed by adjuvant nivolumab in patients with high-risk renal cell carcinoma to determine recurrence-free survival compared with surgery only.

Methods

In this open-label, randomised, phase 3 trial (PROSPER EA8143), patients were recruited from 183 community and academic sites across the USA and Canada. Eligible patients were aged 18 years or older with an Eastern Cooperative Oncology Group performance status of 0–1, with previously untreated clinical stage T2 or greater or T _any N+ renal cell carcinoma of clear cell or non-clear cell histology planned for partial or radical nephrectomy. Selected patients with oligometastatic disease, who were disease free at other disease sites within 12 weeks of surgery, were eligible for inclusion. We randomly assigned (1:1) patients using permuted blocks (block size of 4) within stratum (clinical TNM stage) to either nivolumab plus surgery, or surgery only followed by surveillance. In the nivolumab group, nivolumab 480 mg was administered before surgery, followed by nine adjuvant doses. The primary endpoint was investigator-reviewed recurrence-free survival in patients with renal cell carcinoma assessed in all randomly assigned patients regardless of histology. Safety was assessed in all randomly assigned patients who started the assigned protocol treatment. This trial is registered with ClinicalTrials.gov , NCT03055013 , and is closed to accrual.

Findings

Between Feb 2, 2017, and June 2, 2021, 819 patients were randomly assigned to nivolumab plus surgery (404 [49%]) or surgery only (415 [51%]). 366 (91%) of 404 patients assigned to nivolumab plus surgery and 387 (93%) of 415 patients assigned to surgery only group started treatment. Median age was 61 years (IQR 53–69), 248 (30%) of 819 patients were female, 571 (70%) were male, 672 (88%) were White, and 77 (10%) were Hispanic or Latino. The Data and Safety Monitoring Committee stopped the trial at a planned interim analysis (March 25, 2022) because of futility. Median follow-up was 30·4 months (IQR 21·5–42·4) in the nivolumab group and 30·1 months (21·9–41·8) in the surgery only group. 381 (94%) of 404 patients in the nivolumab plus surgery group and 399 (96%) of 415 in the surgery only group had renal cell carcinoma and were included in the recurrence-free survival analysis. As of data cutoff (May 24, 2023), recurrence-free survival was not significantly different between nivolumab (125 [33%] of 381 had recurrence-free survival events) versus surgery only (133 [33%] of 399; hazard ratio 0·94 [95% CI 0·74–1·21]; one-sided p=0·32). The most common treatment-related grade 3–4 adverse events were elevated lipase (17 [5%] of 366 patients in the nivolumab plus surgery group vs [ < 1%] in the surgery only group), anaemia (seven [2%] vs nine [2%]), increased alanine aminotransferase (ten [3%] vs one [ < 1%]), abdominal pain (four [1%] vs six [2%]), and increased serum amylase (nine [2%] vs none). 188 (51) patients in the nivolumab plus surgery group and 118 (31) in the surgery only group had grade 3–5 adverse events due to any cause, the most common of which were anaemia (26 [7%] vs 20 [5%]), hypertension (30 [8%] vs fifteen [4%]), and elevated lipase (19 [5%] vs seven [2%]). 48 (12%) of 404 patients in the nivolumab group and 40 (10%) of 415 in the surgery only group died, of which nine (2%) and three (1%), respectively, were determined to be treatment-related.

Interpretation

Perioperative nivolumab before nephrectomy followed by adjuvant nivolumab did not improve recurrence-free survival versus surgery only followed by surveillance in patients with high-risk renal cell carcinoma.

Funding

US National Institutes of Health National Cancer Institute and Bristol Myers Squibb.

Le texte complet de cet article est disponible en PDF.

Plan

Introduction

Methods

Study design and participants

Randomisation and masking

Procedures

Outcomes

Statistical analysis

Role of the funding source

Export

Vol 25 - N° 8

P. 1038-1052 - août 2024 Retour au numéro

Article précédent

Interpretable artificial intelligence to optimise use of imatinib after resection in patients with localised gastrointestinal stromal tumours: an observational cohort study
Dimitris Bertsimas, Georgios Antonios Margonis, Suleeporn Sujichantararat, Angelos Koulouras, Yu Ma, Cristina R Antonescu, Murray F Brennan, Javier Martín-Broto, Seehanah Tang, Piotr Rutkowski, Martin E Kreis, Katharina Beyer, Jane Wang, Elzbieta Bylina, Pawel Sobczuk, Antonio Gutierrez, Bhumika Jadeja, William D Tap, Ping Chi, Samuel Singer

| Article suivant

Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study
Guihong Wan, Wenxin Chen, Sara Khattab, Katie Roster, Nga Nguyen, Boshen Yan, Ahmad Rajeh, Jayhyun Seo, Hannah Rashdan, Leyre Zubiri, Matthew J Hadfield, Shadmehr Demehri, Kun-Hsing Yu, William Lotter, Alexander Gusev, Nicole R LeBoeuf, Kerry L Reynolds, Shawn G Kwatra, Yevgeniy R Semenov

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study - 30/07/24

Summary

Background

Methods

Findings

Interpretation

Funding

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL